Anlon Healthcare Ltd

Anlon Healthcare Limited has successfully incorporated a new subsidiary, 'ANLON BIOLOGICS PRIVATE LIMITED', with effect from July 10, 2026. This move aligns with the company's long-term growth objectives and aims to strategically complement and expand its existing business in the pain management segment by manufacturing surgical implants and medical devices. The subsidiary will also focus on the development and manufacture of peptides, biosimilars, and biological compositions. Anlon Healthcare Limited holds a 65% stake in the newly incorporated entity, having subscribed to equity shares worth ₹650,000.

Anlon Healthcare Limited has announced the incorporation of its wholly-owned subsidiary, ANLON MEDICARE PRIVATE LIMITED, effective July 09, 2026. This new entity, with a CIN U21006GJ2026PTC180329, will focus on manufacturing surgical implants and medical devices. The incorporation is part of Anlon Healthcare's strategy to complement and expand its existing business in the pain management segment, leveraging significant growth opportunities in the sector. The subsidiary has an authorized share capital of ₹5,000,000 and a paid-up share capital of ₹2,000,000. Anlon Healthcare Limited has subscribed to equity shares worth ₹1,100,000, holding 55% of the subsidiary's share capital.

Anlon Healthcare Ltd announced that its Chairman & Managing Director, Mr. Punitkumar Rasadia, participated in an interview/podcast on July 06, 2026. The discussion covered the company's business performance, industry outlook, operational updates, growth strategy, future plans, capital expenditure, and financial performance guidance. No unpublished price sensitive information (UPSI) was shared during the interaction. The interview is accessible via provided links on YouTube, Facebook, Instagram, X, and LinkedIn.

Anlon Healthcare Ltd announced that its Chairman & Managing Director, Mr. Punitkumar Rasadia, participated in an interview with Money TV on June 30, 2026. The discussion covered the company's business performance, industry outlook, operational updates, growth strategy, future plans, capital expenditure, financial guidance, and potential acquisitions/disinvestments. Importantly, no unpublished price sensitive information (UPSI) was disclosed during the interview. Links to the interview on the Money TV website and YouTube were provided.

Anlon Healthcare Ltd announced the outcome of its Board Meeting held on July 01, 2026. The Board approved the incorporation of two new wholly-owned subsidiary companies: ANLON MEDICARE PRIVATE LIMITED and ANLON BIOLOGICS PRIVATE LIMITED. Additionally, the Board approved the change in name of an existing subsidiary, REMEMBER INDIA HEALTH LINKS PRIVATE LIMITED, to ANLON MEDICOS PRIVATE LIMITED, subject to MCA approval. The company plans to invest up to ₹1,100,000 in ANLON MEDICARE PRIVATE LIMITED, acquiring 55% of its equity share capital at face value.

Anlon Healthcare Ltd has announced the closure of its trading window for dealing in the company's securities. This closure is effective from Wednesday, July 01, 2026, and will remain in effect until 48 hours after the declaration of the Unaudited Financial Results for the Quarter ended June 30, 2026. The restriction applies to promoters, directors, key managerial personnel, designated employees, connected persons, and their immediate relatives, in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015.

Anlon Healthcare Ltd announced that its Chairman & Managing Director, Mr. Punitkumar Rasadia, has been invited for a television interview on NDTV Profit. The interview, titled "The Small Cap Buzzers," is scheduled for June 11, 2026, at 01:30 PM IST. The discussion will cover the company's growth journey, recent developments, financial performance for FY 2025-26, and future outlook, using only publicly available information. The company emphasized that no unpublished price-sensitive information (UPSI) will be disclosed. The interview may be subject to cancellation or rescheduling.

Anlon Healthcare Ltd announced that its Chairman & Managing Director, Mr. Punitkumar Rasadia, was interviewed on Money TV's program 'Result Analysis for You (RAY)'. The interview, aired on Money TV and available on their website and YouTube, covered the company's financial performance for FY 2025-26, business developments, and industry outlook. The company explicitly stated that no unpublished price sensitive information (UPSI) was shared during the interaction, and all discussed information is already in the public domain. The interview links were provided for public access.

Anlon Healthcare Ltd reported strong FY26 results with a 43% increase in revenue, 48% growth in EBITDA, and a 42% rise in PAT. Consolidated total income reached ₹172.22 Cr, EBITDA stood at ₹47.77 Cr, and PAT at ₹29.09 Cr. The company's growth was fueled by increased demand, operational efficiencies, and strategic acquisitions, including Bizotic Lifescience. Anlon Healthcare is focused on expanding its product portfolio and regulated-market presence, aiming for a 30% revenue CAGR over the next three years with EBITDA margins between 25-30%.

Anlon Healthcare Ltd has released its audited standalone and consolidated financial results for the year ended March 31, 2026. The results were approved at a board meeting held on May 29, 2026, along with a declaration for an unmodified opinion on the audited financial results and a statement of deviation or variation for issue proceeds.